uburyo bushya bwo kuvura kanseri y'ibihaha

Kanseri y'ibihaha itari ntoya (NSCLC) nimwe mu mpamvu zitera impfu ziterwa na kanseri ku isi. Kubwamahirwe, iterambere ryingenzi muburyo bwo kuvura riragaragara, ritanga ibyiringiro bishya kubisubizo byiza hamwe nubuzima bwiza. Iyi ngingo irasesengura ibishya uburyo bushya bwo kuvura kanseri y'ibihaha, harimo kuvura bigamije, immunotherapie, imiti ya chimiotherapie, hamwe nubuvuzi bushya bwo kwa muganga. Kumva Kanseri y'ibihaha itari mito mito (NSCLC) Kanseri y'ibihaha itari mito mito (NSCLC) ni ubwoko bwa kanseri y'ibihaha ikunze kugaragara, bingana na 80-85% by'indwara zose za kanseri y'ibihaha. Irimo ubwoko butandukanye, harimo adenocarcinoma, kanseri y'udukoko twa kanseri, na kanseri nini ya selile. Icyiciro cya NSCLC mugupima kigira ingaruka zikomeye kumahitamo no kuvura. Icyiciro cya mbere NSCLC irashobora kuvurwa no kubagwa, mugihe ibyiciro byateye imbere akenshi bisaba guhuza imiti. Ubu buryo bwo kuvura bukora neza kandi bukagira ingaruka nke ugereranije na chimiotherapie gakondo. Intego rusange muri NSCLC zirimo EGFR, ALK, ROS1, BRAF, na MET.EGFR InhibitorEpidermal growth factor reseptor (EGFR) ni poroteyine ifasha selile gukura no kugabana. Ibibyimba bimwe na bimwe bya NSCLC bifite ihindagurika muri gene ya EGFR, biganisha ku mikurire ya selile itagenzuwe. Inzitizi za EGFR, nka gefitinib, erlotinib, afatinib, na osimertinib, zihagarika ibikorwa bya EGFR, bidindiza cyangwa bihagarika gukura kw'ibibyimba.Inyungu: Akenshi bigira ingaruka nziza kubarwayi bafite ihindagurika rya EGFR, biganisha ku mibereho myiza no kubaho neza.Ingaruka zo ku ruhande: Kurwara uruhu, impiswi, umunaniro.Osimertinib niwo muti wambere wokuvura kumurongo wa mbere wa EGFR wahinduwe na NSCLC, ugaragaza imikorere myiza ugereranije nibisekuruza bya EGFR byabanje. Urashobora kwiga byinshi kubyerekeranye na EGFR inhibitor kuva kuri Urubuga rwa Sosiyete y'Abanyamerika.ALK InhibitorAnaplastique lymphoma kinase (ALK) niyindi poroteyine ishobora guhinduka muri NSCLC. ALK inhibitor, nka crizotinib, ceritinib, alectinib, brigatinib, na lorlatinib, yibasira proteine ​​ALK, ikabuza ibikorwa byayo kandi ikabuza gukura kw'ibibyimba.Inyungu: Nibyiza kubarwayi bafite gahunda ya ALK, bigatuma ubuzima bubaho neza kandi bikagabanya iterambere ryindwara.Ingaruka zo ku ruhande: Guhindura iyerekwa, isesemi, kuruka, impiswi, umunaniro.Alectinib na Lorlatinib bakunze kuvurwa kumurongo wa mbere kubera imikorere yabo myiza hamwe nubushobozi bwo kwinjira mumyanya yubwonko bwamaraso, bifite akamaro kubarwayi bafite metastase yubwonko. Ubushakashatsi bwa Kanseri mu Bwongereza itanga amakuru yinyongera.ROS1 InhibitorROS1 ni reseptor tyrosine kinase, iyo ihujwe nindi gen, ishobora gutera kanseri gukura. Inhibitori ya ROS1, nka crizotinib na entrectinib, zikoreshwa mukuvura NSCLC hamwe na ROS1.Inyungu: Kugabanuka kw'ibibyimba bikomeye no kubaho igihe kirekire kubarwayi bafite ROS1-nziza ya NSCLC.Ingaruka zo ku ruhande: Kimwe na ALK inhibitor.Entrectinib yerekanye amasezerano kubera ubushobozi bwayo bwo kurenga inzitizi yubwonko bwamaraso, bigatuma ikora neza metastase yubwonko. Reba i Urubuga rw’ikigo cy’ubuvuzi cy’i Burayi kumakuru arambuye.Immunotherapy ya NSCLCImmunotherapy ikoresha imbaraga za sisitemu yumubiri yumubiri yo kurwanya kanseri. Inhibitori ya immunite ni ubwoko bwa immunotherapie ibuza poroteyine zibuza sisitemu yumubiri kwibasira kanseri ya kanseri. Inhibitori ya PD-1 / PD-L1, nka pembrolizumab, nivolumab, atezolizumab, na durvalumab, ifunga izo poroteyine, bigatuma sisitemu y’umubiri imenya no gutera kanseri ya kanseri.Inyungu: Ibisubizo biramba kandi bitezimbere kubaho mubice byabarwayi bafite NSCLC.Ingaruka zo ku ruhande: Ingaruka ziterwa na immunite, nka pneumonitis, colitis, na hepatite.Pembrolizumab ikunze gukoreshwa nkumuti wambere kubarwayi ba NSCLC bafite imvugo ya PD-L1. Ibisobanuro byinshi murashobora kubisanga kuri Urubuga rwa FDA.CTLA-4 InhibitorCytotoxic T-lymphocyte ifitanye isano na poroteyine 4 (CTLA-4) niyindi poroteyine ishobora guhagarika sisitemu yumubiri. Ipilimumab ni inhibitor ya CTLA-4 ishobora gukoreshwa ifatanije na PD-1 inhibitor kugirango yongere ubudahangarwa bw'umubiri urwanya kanseri.Inyungu: Urashobora guteza imbere kubaho iyo uhujwe na PD-1 inhibitor.Ingaruka zo ku ruhande: Ingaruka zingirakamaro zijyanye n’ubudahangarwa ugereranije na PD-1 inhibitor yonyine.Ubushakashatsi bwa chimiotherapie Mugihe mugihe imiti igamije kuvura hamwe nubudahangarwa bwahinduye imiti ya NSCLC, chimiotherapie iracyari amahitamo yingenzi, cyane cyane hamwe nubundi buvuzi. Uburyo bushya bwo kuvura kanseri y'ibihaha akenshi bikubiyemo guhuza chimiotherapie na immunotherapie cyangwa imiti igamije kongera imbaraga zabo.ChemoimmunotherapyCombining chimiotherapie na immunotherapie yerekanye ibisubizo bitanga umusaruro muri uburyo bushya bwo kuvura kanseri y'ibihaha. Ubu buryo bukoresha ubushobozi bwa chimiotherapie yangiza kanseri ya kanseri no kurekura antigene, bigatuma bashobora kwibasirwa n’ubudahangarwa bw'umubiri. Kwiyongera kwa immunotherapie birashobora noneho kongera imbaraga zumubiri, biganisha kumusubizo mwiza.Inyungu: Kunoza kubaho no gusubiza ugereranije na chimiotherapie yonyine.Ingaruka zo ku ruhande: Kwiyongera kwingaruka ziterwa na chimiotherapie hamwe ningaruka ziterwa n’ubudahangarwa.Ubuvuzi bugamije hamwe na Chimiotherapie Kwivanga Mu bihe bimwe na bimwe, guhuza imiti igamije hamwe na chimiotherapie bishobora kuba ingirakamaro, cyane cyane ku barwayi bagize imiti yo kurwanya imiti yonyine. Ubu buryo burashobora gufasha kunesha uburyo bwo guhangana no kunoza ibisubizo byubuvuzi.Inyungu: Irashobora kugarura ibyiyumvo byubuvuzi bugamije no guteza imbere ubuzima.Ingaruka zo ku ruhande: Kongera ibyago byingaruka ziterwa nubuvuzi bwombi.Igeragezwa rya Clinical: Kazoza k'Ubuvuzi bwa NSCLCIgeragezwa rya kliniki ni ubushakashatsi bwakozwe busuzuma uburyo bushya bwo kuvura kanseri y'ibihaha n'ingamba. Kwitabira ikizamini cyamavuriro birashobora gutanga uburyo bwo kuvura butaraboneka henshi. Ikigo cy’ubushakashatsi cya kanseri ya Shandong Baofa cyiyemeje guteza imbere ubushakashatsi bwa kanseri kandi gitanga serivisi kandi kigira uruhare mu igeragezwa ry’amavuriro ritanga uburyo bwo kuvura indwara zitaraboneka henshi. Wige byinshi kubyerekeye ibizamini byubuvuzi muri Shandong Baofa Kanseri Yubushakashatsi.Gukoresha imiti mu bigeragezo bya ClinicalIcyizere cyose uburyo bushya bwo kuvura kanseri y'ibihaha kuri ubu barimo gusuzumwa mu bigeragezo bivura, harimo:Antibody-ibiyobyabwenge conjugate (ADCs): Iyi miti itanga imiti ivura kanseri ya kanseri, bikagabanya kwangirika kwingirabuzimafatizo.Antibodies zidasanzwe: Izi antibodies zihuza ingirabuzimafatizo za kanseri hamwe na selile z'umubiri, zikabahuza hamwe kugirango zongere ubudahangarwa bw'umubiri.Ubuvuzi bwa selile (urugero, CAR-T ivura selile): Ubu buvuzi bukubiyemo guhindura ingirabuzimafatizo zigamije kurwanya no gusenya kanseri ya kanseri. Kubana na NSCLC: Umutungo hamwe na SupportLiving hamwe na NSCLC birashobora kuba ingorabahizi, ariko amikoro menshi hamwe nitsinda ryunganira rirahari kugirango rifashe abarwayi nimiryango yabo guhangana niyi ndwara. Tekereza gushakisha umutungo uva mumashyirahamwe nka Ishyirahamwe ry’ibihaha muri Amerika cyangwa i LUNGevity Foundation.Inshingano: Iyi ngingo igamije amakuru gusa kandi ntigomba gufatwa nkinama zubuvuzi. Nyamuneka saba abashinzwe ubuzima kugirango bagusabe ibyifuzo byihariye byo kuvura.